The Conference boosted many stocks as you might expect in a bull market for biotech. We reviewed rather quickly some of the presentations from the JPMorgan Healthcare Conference and will comment on specific companies and stocks in a series of posts.

After four weeks of consecutive gains, the US stock market declined with increased volatility, as September kicked in, a month which is considered to be a tough one for stocks historically.

Vir Biotechnology, Inc., today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of its common stock at a price to the public of $42.00 per share.

Friday was a risk-off day for biotech stocks as the XBI​ took a 3.28% hit on profit taking and concerns that the pandemic could drag on through the summer.

Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.

CICC Capital closed a $229 million investment fund for biologics, with investments coming mainly from Chinese organizations inside and outside the biopharma industry. Some of the money will go to companies making COVID-19 vaccines and therapies.

This China originated virus is has now crossed international borders sparking concern this outbreak will become a pandemic. The stock market dropped 1% Friday due to fears of this outbreak, but some equities have been seeing massive fear gains.